Name (Synonyms) | Correlation | |
---|---|---|
drug1043 | Experimental Group Wiki | 1.00 |
drug2223 | Presatovir Wiki | 0.50 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D018357 | Respiratory Syncytial Virus Infections NIH | 0.41 |
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19 addressing a serious and emergent unmet medical need. This is a randomized, double-blind study of atovaquone therapy in adult participants hospitalized with COVID-19. Approximately 60 participants who meet all eligibility criteria may be randomized in a 2:1 atovaquone/placebo ratio into one of the following treatment groups: Treatment Group 1: continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days Treatment Group 2: continued standard of care therapy together with matching placebo
Description: Log copy number/ml by RT-PCR) from saliva collection at Day 8 from trial entry, or at hospital discharge
Measure: Viral Load Time: Up to 16 days